Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant atezolizumab versus placebo in ctDNA-positive high-risk muscle-invasive bladder cancer after cystectomy
MOH_2021-05-13_009975Phase 3Active, not recruiting
- Sponsor
- Roche Pharmaceuticals Israel
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma of the bladder (TCC) and bladder cancer comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on MOH_2021-05-13_009975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-13_009975.